BioCentury
ARTICLE | Company News

Galapagos, AbbVie restructure CF partnership

October 26, 2018 9:15 PM UTC

Following a mid-year setback, Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) and AbbVie Inc. (NYSE:ABBV) restructured a 2013 deal to develop and commercialize oral potentiators and correctors of mutations in the CFTR gene.

AbbVie will have exclusive, worldwide rights to most programs covered under the deal, including a triple combination therapy. Galapagos retains rights outside of cystic fibrosis to GLPG2737, a CF transmembrane conductance regulator (CFTR) corrector...